Quirónsalud crece un 4% en el primer semestre, con 2.839 millones

Quirónsalud, the largest private hospital network in Spain and a subsidiary of the German Fresenius healthcare and pharmaceutical group, reported a 4% rise in revenue to €2.839 million in the first half of the year, compared to the same period last year. This growth was also 4% in the second quarter, with earnings of €1.430 million, driven by solid organic performance and favorable pricing in Spain, as well as the Labor Risk Prevention business.

However, activity in Colombian hospitals, where Quirónsalud has several healthcare centers, had a modest impact.

The German subsidiary Fresenius Helios, Quirónsalud's main business, generated €7.027 million up to June, marking a 4% increase. This included revenues from hospitals in Germany (Helios Germany) amounting to €4.188 million, a 3% rise, and Helios Spain, contributing €3.995 million, an 8% increase. Fresenius Helios' operating profit (ebit) increased by 11% to €741 million, with a margin of 10.6%, up from 9.9% in the corresponding period last year. The ebit from Helios Germany rose by 13%, while Helios Spain saw an 8% increase.

Fresenius Helios reported an 11% rise in operating profit (ebit) to €741 million, with an ebit margin of 10.6% in the first half. The net profit of the German group Fresenius increased by 12%, with an ebit of €1.397 million, up 7%, and total revenue of €11.608 million, up 4%. Fresenius Kabi, the other division, reported €4.395 billion in revenue up to June, a 3% rise, and an ebit of €740 million, a 5% increase.

Its ebit margin stood at 12%. In the second quarter, Fresenius Kabi saw strong growth, with sales up 6%, largely driven by its bio-pharmaceutical segment, which expanded by 31% to €4.395 billion, especially thanks to the successful launch of its Tyenne biosimilar in the U.S. and Europe. For 2026, Fresenius expects organic revenue growth between 4% and 7%.